LLR Continence Formulary Review Group Terms of Reference(190 KB)
Date added: 31st Dec 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| COLONIS melatonin 1mg/1ml liquid | Do not prescribe | Insomnia and Jet Lag |
This brand due to excipient content is not approved for use in LLR. Please note, this formulation of melatonin 1mg/1ml oral solution is contraindicated in children as it contains excipients at levels which can cause harm in children. |
| LEFLUNOMIDE (UPDATED) | Orange | Rheumatological disease | |
| MELATONIN | Yellow | Free running circadian rhythm and delay sleep phase syndrome in adults and children. |
Initiated by UHL sleep services. |
| MELATONIN (doses of 10mg daily or less) | Yellow | Sleep disorders in children with Attention Deficit Hyperactive Disorder (ADHD), autism, visual impairment, learning difficulties, developmental delay and Smith-Magenis syndrome, as outlined in LLR APC guidance. Continued in adults if proven efficacy in childhood |
Yellow only applies to the products stated in the LLR APC guidance. Other formulations are secondary care only. |
| MELATONIN M/R 1mg and 5mg tablets (Slenyto®) | Yellow | For for treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. | |
| MERCAPTOPURINE (UPDATED) | Orange | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) & Autoimmune Hepatitis | |
| Relugolix (Orgovyx®) (UPDATED) | Yellow | For treating hormone sensitive prostate cancer |
Restricted to patients who would otherwise have been prescribed Degarelix.
|
| VENLAFAXINE | Green | Depression (All doses) |
SBAR: Change to Venlafaxine Shared Care Arrangements Dose-related increases in blood pressure have been commonly reported with venlafaxine. All patients should be carefully screened for high blood pressure and pre-existing hypertension should be controlled before initiation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment and after dose increases. |
Other Updates on this Website
Recent documents from LLR APC and TAS
Respiratory Prescribing Group Minutes September 2025(192 KB)
Date added: 29th Dec 2025
Respiratory Prescribing Group Minutes June 2025(216 KB)
Date added: 29th Dec 2025
SBAR: Change to Venlafaxine Shared Care Arrangements(107 KB)
Date added: 4th Dec 2025
Adult Emergency Allergy Action Plan Guidance(154 KB)
Date added: 3rd Dec 2025
LLR APC Meeting Minutes November 2025(318 KB) - LMSG/LLR APC minutes
Date added: 3rd Dec 2025
Antimicrobial Guide for Primary Care(1 MB) - Guidelines
Date added: 2nd May 2019
Paediatric Emergency Allergy Action Plan Guidance(148 KB) - Guidelines
Date added: 10th Oct 2018
Allergy: Emergency Action Plan with EpiPen®(2 MB) - Guidelines
Date added: 13th Dec 2017
Allergy: Emergency Action Plan with Jext®(2 MB) - Guidelines
Date added: 13th Dec 2017
SCA: Tacrolimus Historic Renal transplant patients(363 KB) - Guidelines
Date added: 22nd May 2015
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more